You may have access to the free features available through My Research. You can save searches, save documents, create alerts and more. Please log in through your library or institution to check if you have access.
If you log in through your library or institution you might have access to this article in multiple languages.
Styles include MLA, APA, Chicago and many more. This feature may be available for free if you log in through your library or institution.
You may have access to it for free by logging in through your library or institution.
You may have access to different export options including Google Drive and Microsoft OneDrive and citation management tools like RefWorks and EasyBib. Try logging in through your library or institution to get access to these tools.
You might have access to the full article...
Try and log in through your institution to see if they have access to the full text.
Bayer thought it might be able to expand Xofigo in prostate cancer by testing it with Johnson & Johnson’s Zytiga. But that plan has hit a snag.
The German drugmaker unblinded a phase 3 study combining the two meds with steroids after an independent data monitoring committee identified more fractures and deaths in the Xofigo arm. Now, the company is raising the curtain on the study “to thoroughly analyze the data,” Mike Devoy, Bayer’s chief medical officer, said...